GREENLAND MINES LTD (GRML) Stock Price & Overview
NASDAQ:GRML • US49876K1034
Current stock price
The current stock price of GRML is 0.42 USD. Today GRML is up by 19.59%.
GRML Key Statistics
- Market Cap
- 50.921M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.33
- Dividend Yield
- N/A
GRML Stock Performance
GRML Stock Chart
GRML Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to GRML.
GRML Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GRML. While GRML has a great health rating, there are worries on its profitability.
GRML Earnings
GRML Forecast & Estimates
GRML Groups
Sector & Classification
GRML Financial Highlights
Over the last trailing twelve months GRML reported a non-GAAP Earnings per Share(EPS) of -0.33. The EPS decreased by -38.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -112.08% | ||
| ROE | -113.73% | ||
| Debt/Equity | 0 |
GRML Ownership
GRML Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.31 | 375.559B | ||
| AMGN | AMGEN INC | 15.58 | 191.693B | ||
| GILD | GILEAD SCIENCES INC | 16.07 | 176.393B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.05 | 113.496B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.42 | 81.177B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.06 | 42.608B | ||
| INSM | INSMED INC | N/A | 34.4B | ||
| NTRA | NATERA INC | N/A | 28.771B | ||
| BIIB | BIOGEN INC | 11.02 | 25.993B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.24 | 25.192B | ||
| MRNA | MODERNA INC | N/A | 20.253B | ||
| INCY | INCYTE CORP | 12.66 | 19.296B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.068B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GRML
Company Profile
Klotho Neurosciences, Inc. operates with two divisions: Natural Resources and Cell and Gene Therapy. The Natural Resources division is focused on the exploration and development of the Skaergaard Project in Southeast Greenland, which is undeveloped palladium, gold, and platinum deposits. The Skaergaard Project is located in Southeast Greenland, which is an undeveloped palladium, gold, and platinum deposit. It operates three Mineral Exploration Licenses (MEL): MEL 2007-01, MEL 2012-25, and MEL 2021-10. The Cell and Gene Therapy division includes the Company's KLTO-202 primary indication for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s Disease). It is engaged in developing and providing new therapies to alleviate and/or reverse the progression of neurodegenerative diseases through the use of cell and gene therapy. It is also focusing on developing therapeutic agents for the treatments for Alzheimer's and Parkinson's disease.
Company Info
IPO: 2022-04-29
GREENLAND MINES LTD
1300 South Boulevard, Suite D
Omaha NORTH CAROLINA US
Employees: 3
Phone: 13028948922
GREENLAND MINES LTD / GRML FAQ
What does GRML do?
Klotho Neurosciences, Inc. operates with two divisions: Natural Resources and Cell and Gene Therapy. The Natural Resources division is focused on the exploration and development of the Skaergaard Project in Southeast Greenland, which is undeveloped palladium, gold, and platinum deposits. The Skaergaard Project is located in Southeast Greenland, which is an undeveloped palladium, gold, and platinum deposit. It operates three Mineral Exploration Licenses (MEL): MEL 2007-01, MEL 2012-25, and MEL 2021-10. The Cell and Gene Therapy division includes the Company's KLTO-202 primary indication for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s Disease). It is engaged in developing and providing new therapies to alleviate and/or reverse the progression of neurodegenerative diseases through the use of cell and gene therapy. It is also focusing on developing therapeutic agents for the treatments for Alzheimer's and Parkinson's disease.
What is the current price of GRML stock?
The current stock price of GRML is 0.42 USD. The price increased by 19.59% in the last trading session.
Does GREENLAND MINES LTD pay dividends?
GRML does not pay a dividend.
What is the ChartMill technical and fundamental rating of GRML stock?
GRML has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How many employees does GREENLAND MINES LTD have?
GREENLAND MINES LTD (GRML) currently has 3 employees.
What is the market capitalization of GRML stock?
GREENLAND MINES LTD (GRML) has a market capitalization of 50.92M USD. This makes GRML a Micro Cap stock.